This content is machine translated Risankizumab as a therapeutic option “Real life” interim balance: PASI 100 – realistic target Risankizumab has been approved in Switzerland since April 2019 for moderate to severe plaque psoriasis after unsuccessful therapy with conventional systemic treatment. The high and long-lasting efficacy with rapid response…
